HHS said Friday the company will use the funds to conduct large-scale production and Phase 3 trials of the experimental AZD7442 combo drug to help prevent or treat SARS-CoV-2 infections.
The biopharmaceutical firm licensed the two antibodies from Vanderbilt University and extended the compounds' duration of action using a proprietary technology.
According to HHS, the antiviral cocktail is intended to neutralize the novel coronavirus and reduce its ability to infect cells in the human body.
The federal government plans to widely distribute AZD7442 if the product receives approval from the Food and Drug Administration as part of Operation Warp Speed.
The U.S. Space Force plans to modify its Andromeda indefinite-delivery/indefinite-quantity contract to raise the total ceiling to $6.24 billion. Lockheed Martin,…
CACI International has appointed Christopher Monoski as executive vice president of manufacturing. Monoski will report to President and CEO John Mengucci and join…
